POLYUNSATURATED FATTY ACIDS

FA-014
Linoleic acid (18:2, n-6)
Octadeca-9Z,12Z-dienoic acid
99%, MW=280.4 [60-33-3] Storage: -20°C
100 mg
1 g

FA-005
Linolenic acid (18:3, n-3)
Octadeca-9Z,12Z,15Z-trienoic acid
99%, MW=278.4 [463-40-1] Storage: -20°C
100 mg
1 g

FA-006
g-linolenic acid (18:3, n-6)
Octadeca-6Z,9Z,12Z-trienoic acid
99%, MW=278.4 [506-26-3] Storage: -20°C.
Antitumor activity¹. Beneficial effects in liver cancer patients².
100 mg
1 g

FA-024
Eicosa-5Z, 8Z-dienoic acid (20:2, n-12)
99%, MW=308.5, Storage: -20°C
Arachidonic acid analog lacking the C-11 and C-14 double bonds.
1 mg
5 mg

FA-007
Eicosa-11Z,14Z-dienoic acid (20:2, n-6)
99%, MW=308.5 [2091-39-6] Storage: -20°C
Arachidonic acid analog lacking the C-5 and C-6 double bonds.
100 mg
1 g

FA-008
Eicosa-11Z,14Z,17Z-trienoic acid (20:3, n-3)
99%, MW=306.5 [2091-27-2] Storage: -20°C
100 mg
1 g

FA-009
Dihomo-g-linolenic acid (20:3, n-6)
Eicosa-8Z,11Z,14Z-trienoic acid
99%, MW=306.5 [1783-84-2] Storage: -20°C
Beneficial effects in cardiovascular diseases and inflammation³.
100 mg
1 g

FA-004
Mead acid (20:3, n-9)
Eicosa-5Z,8Z,11Z-trienoic acid
95%, MW=306.5 [20590-32-3] Storage: -20°C
Accumulates in tissues of essential fatty acid deficient animals⁴. Is not converted to prostaglandins and LTB₄ but is converted to cysteinyl leukotrienes⁵. Immunomodulatory and anti-inflammatory effects^6,7.
1 mg
10 mg

FM-004
Mead acid methyl ester
99%, MW=320.5 [14602-39-2] Storage: -20°C
1 mg
10 mg

FA-003
Arachidonic acid (20:4, n-6)
Eicosa-5Z,8Z,11Z,14Z-tetraenoic acid
99%, MW=304.5 [506-32-1] Storage: -20°C
Precursor to a large family of eicosanoids^7,8. Acts as a second messenger independent of metabolism^9-12. Retrograde messenger in long-term potentiation in the nervous system¹³. Inhibits Ras-GAP.
100 mg
1 g

FA-001
Eicosa-5Z,8Z,11Z,14Z,17Z-pentaenoic acid (20:5, n-3)
98%, MW=302.5 [10417-94-4] Storage: -20°C
Beneficial effect in cardiovascular diseases¹⁵ and inflammation^16,17.
100 mg
1 g

FA-010
Docosa-13Z,16Z,19Z-trienoic acid (22:3, n-3)
98%, MW=336.5 [28845-86-5] Storage: -20°C
20 mg
100 mg

FA-011
Adrenic acid (22:4, n-6)
Docosa-7Z,10Z,13Z,16Z-tetraenoic acid
98%, MW=332.5 [28874-58-0] Storage: -20°C
20 mg
100 mg

FA-012
Docosa-7Z,10Z,13Z,16Z,19Z-pentaenoic acid (22:5, n-3)
98%, MW=330.5, Storage: -20°C
1 mg
10 mg

FA-002
Docosa-4Z,7Z,10Z,13Z,16Z,19Z-hexaenoic acid (22:6, n-3)
98%, MW=328.5 [6217-54-5] Storage: -20°C
100 mg
1 g

For anandamides and related amides, see Cannabinoids

REFERENCES

1. F. Fujiwara et al. Prostagland. Leukotrienes Med. 1986 23 311

2. C.F. van der Merwe et al. Prostagland. Leukotrienes Essent. Fatty Acids 1990 40 199

3. D.F. Horrobin Prostagland. Leukotrienes Essent. Fatty Acids 1991 44 127

4. J.B. Lefkowith et al. Prostagland. Leukotrienes Med. 1986 23 123

5. J.B. Lefkowith Adv. Prostagland. Thromboxane Leukotriene Res. 1990 20 224

6. G.F. Schreiner et al. Science 1988 240 1032

7. A.L. Willis (ed.) Handbook of Eicosanoids CRC Press, Boca Raton, 1987

8. P. Needleman et al. Annu. Rev. Biochem. 1986 55 69

9. S.B. Abramson et al. J. Immunol. 1991 147 231

10. S.B. Abramson et al. J. Immunol. 1991 147 231

11. C. Dettbarn et al. Biochem. Pharmacol. 1993 45 1301

12. C. Sumida Prostagland. Leukotreines Essent. Fatty Acids 1993 48 117

13. M.A. Lynch et al. Biochem. Soc. Trans. 1991 19 391

14. J.-W. Han et al. Science 1991 252 576

15. J. Mehta et al. Am. J. Cardiol. 1987 59 155

16. T. Terano et al. Biochem. Pharmacol. 1986 35 779

17. T.H. Lee et al. N. Engl. J. Med. 1985 312 1217